Compare Johnson & Johnson (JNJ) vs RLX Technology Inc (RLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs RLX Technology Inc — how do they compare? Johnson & Johnson trades at $249.37 (market cap $598.96B), while RLX Technology Inc trades at $2.03 (market cap $2.52B). The key difference: Johnson & Johnson is far larger — about 237.7× RLX Technology Inc's market cap, and RLX Technology Inc pays the higher dividend (4.85%). Which is the better fit depends on your goals.
| JNJ | RLX | |
|---|---|---|
Market Cap | $598.96B | $2.52B |
Volume | 6,156,228 | — |
Sector | Health | Technology |
52-Week High | $267.24 | $2.73 |
52-Week Low | $164.36 | $1.79 |
Enterprise Value | $631.90B | $1.15B |
Dividend Yield | 2.15% | 4.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
RLX trades at $2.06, up 0.49% today, with a bullish technical signal from moving averages but bearish oscillators. The company reported Q1 2026 revenue growth driven by international expansion, with 2025 revenue of $3.62B and net income of $921.87M. Recent news highlights the vaping industry's projected growth and RLX's cash-rich, debt-free balance sheet.
Outlook is mixed: strong fundamentals and industry tailwinds support growth, but recent EPS misses and a single analyst 'Hold' rating suggest caution. Key risks include regulatory scrutiny and execution challenges in global markets. The stock presents opportunity for long-term investors if expansion succeeds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →
